Despite advanced analytical techniques, much of the cannabis used recreationally is inaccurately classified. One laboratory at the University of British Columbia found that Jamaican Lamb’s Bread, claimed to be 100% sativa, was in fact almost 100% indica (the opposite strain). Legalization of cannabis in Canada (as of October 17, 2018) may help spur private-sector research, especially in terms of diversification of strains. It should also improve classification accuracy for cannabis used recreationally. Legalization coupled with Canadian government (Health Canada) oversight of production and labelling will likely result in more -- and more accurate -- testing to determine exact strains and content. Furthermore, the rise of craft cannabis growers in Canada should ensure quality, experimentation/research, and diversification of strains among private-sector producers.
All other applicable federal and state regulations apply to the production of hemp products for human consumption and other uses (e.g. FDA, DPHHS). This list is not all inclusive and just includes examples of potential products from the pilot program. Pilot participants are allowed to harvest and process any hemp seed, oils, fiber, and hurd that they produce. They may process these items themselves or sell them for processing or use. All hemp produced must be processed before leaving Montana. Commercial production outside the Montana Hemp Pilot Program is not currently allowed under state or federal law.
Individuals are responsible for sourcing their own propagative material. TNHIA is a great resource. All seed or plant material being brought into the state must have prior approval by the Tennessee Department of Agriculture (TDA). Please use our seed and propagule acquisition forms to request approval. If importing from another state use this link: https://www.tn.gov/content/dam/tn/agriculture/documents/planthealth/Domestic_Seed_Import_Requirements.pdf
“The plan? Whip the public into a frenzy over ill effects of marijuana, the psychoactive leaves and flowers of the hemp plant; the reputation of the fibers and seeds used by industry would be posing little threat to society emerged as the ‘assassin of youth.’ The strategy worked. In 1937, with virtually no warning, Congress announced a prohibitive tax on hemp, effectively ending the production and sale of the plant in the United States.
The above uses are based on hemp as a mechanical strengthener of materials. Hemp can also be chemically combined with materials. For example, hemp with gypsum and binding agents may produce light panels that might compete with drywall. Hemp and lime mixtures make a high quality plaster. Hemp hurds are rich in silica (which occurs naturally in sand and flint), and the hurds mixed with lime undergo mineralization, to produce a stone-like material. The technology is most advanced in France (Fig. 26). The mineralized material can be blown or poured into the cavities of walls and in attics as insulation. The foundations, walls, floors, and ceilings of houses have been made using hemp hurds mixed with natural lime and water. Sometimes plaster of Paris (pure gypsum), cement, or sand is added. The resulting material can be poured like concrete, but has a texture vaguely reminiscent of cork—much lighter than cement, and with better heat and sound-insulating properties. An experimental “ceramic tile” made of hemp has recently been produced (Fig. 27).
Jump up ^ Russo, E. B.; Jiang, H.-E.; Li, X.; Sutton, A.; Carboni, A.; Del Bianco, F.; Mandolino, G.; Potter, D. J.; Zhao, Y.-X.; Bera, S.; Zhang, Y.-B.; Lü, E.-G.; Ferguson, D. K.; Hueber, F.; Zhao, L.-C.; Liu, C.-J.; Wang, Y.-F.; Li, C.-S. (2008). "Phytochemical and genetic analyses of ancient cannabis from Central Asia". Journal of Experimental Botany. 59 (15): 4171–82. doi:10.1093/jxb/ern260. PMC 2639026. PMID 19036842.
"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia.
To make matters more confusing, nine states (including California, Washington, and Colorado) let residents buy cannabis-based products with or without THC. Nearly two dozen other “medical marijuana states” allow the sale of cannabis, including capsules, tinctures, and other items containing CBD or THC, at licensed dispensaries to people whose doctors have certified that they have an approved condition (the list varies by state but includes chronic pain, PTSD, cancer, autism, Crohn’s disease, and multiple sclerosis). Sixteen more states legalized CBD for certain diseases. But because all these products are illegal according to the federal government, cannabis advocates are cautious. “By and large, the federal government is looking the other way,” says Paul Armentano, deputy director of the Washington, DC–based National Organization for the Reform of Marijuana Laws (NORML), but until federal laws are changed, “this administration or a future one could crack down on people who produce, manufacture, or use CBD, and the law would be on its side.”
There’s also been a lot of talk lately about “microdosing” CBD. This refers to an incremental process of finding your minimum effective dose. You can do this with any concentration of CBD oil, but lower concentrations will take longer. In a 2017 article in Rolling Stone, Dr. Dustan Sulak outlines his protocol for microdosing. You can begin this process by asking yourself three questions:
An in vitro study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD induced programmed cell death, independent of the CB1, CB2, or vanilloid receptors. CBD inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic mammary cells. Other studies have also shown the antitumor effect of cannabinoids (i.e., CBD and THC) in preclinical models of breast cancer.[19,20]
A 2016 review of animal studies indicated that cannabidiol has potential as an anxiolytic for relief of anxiety-related disorders and fear. Reviews of preliminary research showed cannabidiol has potential for improving addictive disorders and drug dependence, although as of 2016, they indicated limited high-quality evidence for anti-addictive effects in people.
A Cochrane meta-analysis of 23 randomized RCTs reviewed studies conducted between 1975 and 1991 that investigated dronabinol or nabilone, either as monotherapy or as an adjunct to the conventional dopamine antagonists that were the standard antiemetics at that time. The chemotherapy regimens involved drugs with low, moderate, or high emetic potential. The meta-analysis graded the quality of evidence as low for most outcomes. The review concluded that individuals were more likely to report complete absence of N/V when they received cannabinoids compared with placebo, although they were more likely to withdraw from the study because of an adverse event. Individuals reported a higher preference for cannabinoids than placebo or prochlorperazine. There was no difference in the antiemetic effect of cannabinoids when compared with prochlorperazine. The authors concluded that Cannabis-based medications may be useful for treating refractory chemotherapy-induced N/V; however, they cautioned that their assessment may change with the availability of newer antiemetic regimens.
For centuries, industrial hemp (plant species Cannabis sativa) has been a source of fiber and oilseed used worldwide to produce a variety of industrial and consumer products. Currently, more than 30 nations grow industrial hemp as an agricultural commodity, which is sold on the world market. In the United States, however, production is strictly controlled under existing drug enforcement laws. Currently there is no large-scale commercial production in the United States and the U.S. market depends on imports.
The etymology is uncertain but there appears to be no common Proto-Indo-European source for the various forms of the word; the Greek term kánnabis is the oldest attested form, which may have been borrowed from an earlier Scythian or Thracian word. Then it appears to have been borrowed into Latin, and separately into Slavic and from there into Baltic, Finnish, and Germanic languages. Following Grimm's law, the "k" would have changed to "h" with the first Germanic sound shift, after which it may have been adapted into the Old English form, hænep. However, this theory assumes that hemp was not widely spread among different societies until after it was already being used as a psychoactive drug, which Adams and Mallory (1997) believe to be unlikely based on archaeological evidence. Barber (1991) however, argued that the spread of the name "kannabis" was due to its historically more recent drug use, starting from the south, around Iran, whereas non-THC varieties of hemp are older and prehistoric. Another possible source of origin is Assyrian qunnabu, which was the name for a source of oil, fiber, and medicine in the 1st millennium BC.